Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | F12 | P00748 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.58 |
| ▸ | NOS1 | P29475 | 1/20 | 0.58 |
| ▸ | NOS2 | P35228 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923403 | 0.77 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL199273 | 0.77 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL24663121 | 0.75 | CYP2A6 (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL30522769 | 0.75 | PLAU (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL70487 | 0.73 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL1567649 | 0.73 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL1741872 | 0.73 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL1010668 | 0.73 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL58112 | 0.73 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL3675858 | 0.73 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2022-02-17 | — | — | US | disclosed |
| EP-3914249-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | Akribes Biomedical GmbH (AT) | 2021-12-01 | — | — | EP | disclosed |
| CN-113382730-A | Selective glucocorticoid receptor modifiers for treatment of impaired skin wound healing | 阿克里斯生物医药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020152193-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2020-07-30 | — | — | WO | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0151319-B1 | Hexahydrobenzo[de]quinoline derivatives and their preparation | ELI LILLY AND COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| EP-0061341-B1 | 6-SUBSTITUTED HEXAHYDROINDAZOLO ISOQUINOLINES | ELI LILLY AND COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0151319-A1 | Hexahydrobenzo[de]quinoline derivatives and their preparation | ELI LILLY AND COMPANY (US) | 1985-08-14 | — | — | EP | disclosed |
| EP-0061341-A2 | 6-Substituted hexahydroindazolo isoquinolines | ELI LILLY AND COMPANY (US) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | NR3C1, NR3C2, MC2R | PLAU 2696/4885CYP2A6 2248/4885F12 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.